We continuously conduct research and scientific studies to help us ensure that our product has an impact on improving life with diabetes.
On this page, we’ve summarised the results from a retrospective study conducted among our users in 2020. These show the positive outcome that poorly regulated users of Hedia Diabetes Assistant (HDA) experience improved stability of their blood glucose.
HDA users experience significant improvements after 12 weeks of using HDA. Lower A1c indicates increasing control of blood glucose over time.
HDA users increase their estimated time-in-range over 12 weeks. Time-in-range shows the percentage of time in which a person is within their blood glucose target range.
A real-world study investigated changes in blood glucose control in people with type 1 diabetes after 12 weeks use of Hedia Diabetes Assistant. The dataset consisted of anonymised data from 234 engaged users, who had logged 10 or more blood glucose values per week for 12 weeks. The study looked into both the users as a whole, as well as a specific group of 84 users who had an estimated A1c of 7.9% or higher in their first week of using Hedia Diabetes Assistant.
A decrease of 0.78% was detected in the group of more poorly controlled users. A slight decrease in eA1c was detected in the group as a whole, over the 12 weeks.
How was the A1c estimated? A user enters their blood glucose levels into Hedia; over time, Hedia is able to find the average of those blood glucose levels. From this, we can get the “eA1c”: the estimated A1c.
For the 84 users who initially had less blood glucose control, we found a 12.35% improvement in estimated time-in-range after 12 weeks use of Hedia. Across all users, we saw a 2% average increase in time-in-range in 12 weeks use of Hedia Diabetes Assistant. This may indicate that Hedia contributes to maintaining a well-controlled blood glucose level.
The range that we looked at was a blood glucose level between 3.9 and 10 mmol/L. This gave us the estimated time-in-range: the proportion of blood glucose measurements within that range.
Often, a digital divide might present itself between different groups of people. This study, however, is notably absent of any such digital divide regarding sex and age.
In other words, a person’s sex or age made no particular difference to the results: the same benefits appeared for all groups. This study showed Hedia Diabetes Assistant catering for all, regardless of sex or age.
See the full report from the Hedia retrospective study here
Reference: A. Karnoe, M.O. Jakobsen, S.M. Nielsen, N. Ejskjaer, H. Gudbergsen. Clinically relevant improvement in glycaemic control in type 1 diabetes users of the Hedia application for diabetes management: a real-world cohort study, ATTD conference 2021, Diabetes Technology & Therapeutics, 23, A199.
If you have any questions about how we continuously evaluate Hedia Diabetes Assistant, feel free to contact us at support@hedia.co
